Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 3/20 | 0.57 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.48 |
| ▸ | CACNG8 | Q8WXS5 | 2/20 | 0.48 |
| ▸ | PGR | P06401 | 1/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | CMA1 | P23946 | 1/20 | 0.45 |
| ▸ | SMYD3 | Q9H7B4 | 5/20 | 0.44 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.43 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.43 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2611053 | 0.86 | AHR (0.56) | AHRGRIA1CACNG8PGRPDE3B | |
| SCHEMBL9485923 | 0.85 | KIF11 (0.52) | PDE3BPDE3ACYP1A2CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL8917748 | 0.84 | KIF11 (0.51) | PDE3BPDE3ACYP1A2CYP11B1CYP11B2 | |
| SCHEMBL24191820 | 0.83 | AHR (0.53) | AHRGRIA1CACNG8PGRPDE3B | |
| SCHEMBL21983115 | 0.83 | AHR (0.53) | AHRGRIA1CACNG8PGRPDE3B | |
| SCHEMBL24192217 | 0.83 | AHR (0.53) | AHRGRIA1CACNG8PGRPDE3B | |
| SCHEMBL265219 | 0.83 | AHR (0.53) | AHRGRIA1CACNG8PGRPDE3B | |
| SCHEMBL25899777 | 0.83 | AHR (0.53) | AHRGRIA1CACNG8PGRPDE3B | |
| SCHEMBL26025060 | 0.83 | AHR (0.56) | AHRGRIA1CACNG8PGRPDE3B | |
| SCHEMBL24192091 | 0.81 | AHR (0.50) | AHRGRIA1CACNG8PGRPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030191128-A1 | 2-indolinone derivatives as modulators of protein kinase activity | SUGEN, INC. | 2003-10-09 | — | — | US | disclosed |
| US-6569868-B2 | Imidazoly 2-indolinones as anticarcinogenic, -diabetic, -arthritic, -proliferative and inflammatory agents; fibrosis; autoimmune disorder, angiogenesis, restenosis, psoriasis, osteoarthritis and rheumatoid arthritis | SUGEN, INC. | 2003-05-27 | — | — | US | disclosed |
| US-20020028840-A1 | 2-indolinone derivatives as modulators of protein kinase activity | TANG PENG CHO (US) | 2002-03-07 | — | — | US | disclosed |
| US-6316635-B1 | USED IN PROPHYLAXIS AND THERAPY OF PROTEIN KINASE RELATED CELLULAR DISORDERS SUCH AS CANCER, DIABETES, AUTOIMMUNE DISORDER, HYPERPROLIFERATION DISORDER, INFLAMMATORY DISORDER, ANGIOGENESIS, RESTENOSIS, FIBROSIS, PSORIASIS, OSTEOARTHRITIS | SUGEN, INC. | 2001-11-13 | — | — | US | disclosed |
| EP-1066257-A2 | HETEROCYLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | Sugen, Inc. (US) | 2001-01-10 | — | — | EP | disclosed |
| WO-1999048868-A9 | HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | SUGEN INC (US) | 2000-04-20 | — | — | WO | disclosed |
| WO-1999048868-A2 | HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | SUGEN, INC. (US) | 1999-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028840-A1 | 2-indolinone derivatives as modulators of protein kinase activity | DMPK, IP6K2, MAP4K2 | AHR 2285/4885GRIA1 2680/4885CACNG8 3109/4885 |
| US-20030191128-A1 | 2-indolinone derivatives as modulators of protein kinase activity | DMPK, IP6K2, MAP4K2 | AHR 2285/4885GRIA1 2680/4885CACNG8 3109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.